Nitto Avecia Completes Large-Scale Synthesis of Oligonucleotide

Nitto Avecia, a provider of oligonucleotide manufacturing and development services, announced on Nov. 7, 2017 that it had successfully completed the first synthesis runs at the 1.6 Mol-scale, which is believed to be the largest synthesis-scale executed for oligonucleotide active pharmaceutical ingredients (APIs). The run was conducted at its new oligonucleotide manufacturing facility in Milford, MA.

The completed run comes months after the company first brought its new API manufacturing synthesis capabilities on line.  This manufacturing capacity expansion increases the company's total synthesis capacity to more than 3 Mol. 

Nitto Avecia's President Detlef Rethage stated in a company press release: "Avecia's leadership in the oligonucleotide market is significant, and we are proud to have added this major manufacturing scale in less than two years to address a capacity shortage that could have slowed down our client's clinical trial progress. With our 1.6 Mol synthesis capabilities now operational, the capacity shortage in oligonucleotides manufacturing has now been addressed."